SG11201803519YA - A solid state form of pladienolide pyridine compounds and methods of use - Google Patents
A solid state form of pladienolide pyridine compounds and methods of useInfo
- Publication number
- SG11201803519YA SG11201803519YA SG11201803519YA SG11201803519YA SG11201803519YA SG 11201803519Y A SG11201803519Y A SG 11201803519YA SG 11201803519Y A SG11201803519Y A SG 11201803519YA SG 11201803519Y A SG11201803519Y A SG 11201803519YA SG 11201803519Y A SG11201803519Y A SG 11201803519YA
- Authority
- SG
- Singapore
- Prior art keywords
- tsukuba
- eisai
- tokodai
- shi
- rearch
- Prior art date
Links
- 239000007787 solid Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 150000003222 pyridines Chemical class 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 210000001324 spliceosome Anatomy 0.000 abstract 1
- 239000002023 wood Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562257088P | 2015-11-18 | 2015-11-18 | |
| PCT/US2016/062525 WO2017087667A1 (fr) | 2015-11-18 | 2016-11-17 | Forme d'état solide de composés de pladiénolide-pyridine et procédés pour leur utilisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201803519YA true SG11201803519YA (en) | 2018-06-28 |
Family
ID=57472076
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201913045PA SG10201913045PA (en) | 2015-11-18 | 2016-11-17 | A solid state form of pladienolide pyridine compounds and methods of use |
| SG11201803519YA SG11201803519YA (en) | 2015-11-18 | 2016-11-17 | A solid state form of pladienolide pyridine compounds and methods of use |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201913045PA SG10201913045PA (en) | 2015-11-18 | 2016-11-17 | A solid state form of pladienolide pyridine compounds and methods of use |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10745387B2 (fr) |
| EP (1) | EP3377485B1 (fr) |
| JP (2) | JP6312282B2 (fr) |
| KR (1) | KR20180083376A (fr) |
| CN (1) | CN108473479B (fr) |
| AU (2) | AU2016357433B2 (fr) |
| BR (1) | BR112018009995B1 (fr) |
| CA (1) | CA3004623C (fr) |
| ES (1) | ES2757174T3 (fr) |
| IL (1) | IL259198B2 (fr) |
| MD (1) | MD3377485T2 (fr) |
| MX (2) | MX392475B (fr) |
| RU (2) | RU2743349C2 (fr) |
| SG (2) | SG10201913045PA (fr) |
| WO (1) | WO2017087667A1 (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210006907A (ko) * | 2018-04-09 | 2021-01-19 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 플라디에놀리드 화합물 및 그의 용도 |
| WO2019200100A1 (fr) | 2018-04-12 | 2019-10-17 | Andrew Cook | Dérivés de pladiénolide en tant qu'agents ciblant un complexe d'épissage pour le traitement du cancer |
| CN112367996B (zh) * | 2018-06-01 | 2024-05-24 | 卫材R&D管理有限公司 | 使用剪接调节剂的方法 |
| WO2021113755A2 (fr) * | 2019-12-04 | 2021-06-10 | Pai Athma A | Oligonucléotides anti-slc6a1 et procédés associés |
| US12043670B2 (en) * | 2020-06-05 | 2024-07-23 | Eisai R&D Management Co., Ltd. | Anti-BCMA antibody-drug conjugates and methods of use |
| KR20230104204A (ko) | 2020-11-04 | 2023-07-07 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 골수이형성 증후군(mds)에 대한 바이오마커 및 이를 사용하는 방법 |
| WO2023131866A1 (fr) | 2022-01-05 | 2023-07-13 | Eisai R&D Management Co., Ltd. | Biomarqueurs pour le syndrome myélodysplasique (mds) et leurs méthodes d'utilisation |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI311558B (en) * | 2001-02-01 | 2009-07-01 | Mercian Corporatio | Novel physiologically active substance |
| TWI334866B (en) | 2002-05-29 | 2010-12-21 | Mercian Corp | Novel physiologically active substances |
| JP4459051B2 (ja) | 2002-07-31 | 2010-04-28 | メルシャン株式会社 | 新規生理活性物質 |
| KR101285695B1 (ko) | 2002-07-31 | 2013-07-12 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 신규한 생리 활성 물질 |
| WO2004037212A2 (fr) | 2002-10-24 | 2004-05-06 | Sepracor, Inc. | Compositions contenant des derives du zopiclone, et leurs procedes de preparation et d'utilisation |
| CA2507641A1 (fr) | 2002-11-29 | 2004-06-17 | Mercian Corporation | Procede de production d'un compose macrolide |
| CA2546614A1 (fr) | 2003-11-27 | 2005-06-09 | Mercian Corporation | Adn intervenant dans l'hydroxylation d'un compose macrolide |
| EP1702982B1 (fr) | 2003-11-28 | 2010-05-05 | Kanagawa Academy Of Science And Technology | Methode de detection, diagnostic et remede contre le cancer du foie |
| JPWO2006003706A1 (ja) | 2004-07-02 | 2008-04-17 | 株式会社プラスワンテクノ | 組み合わせ計量技術 |
| CN1977046A (zh) | 2004-07-20 | 2007-06-06 | 卫材R&D管理有限公司 | 编码参与普拉地内酯生物合成的多肽的dna |
| TW200716744A (en) | 2005-05-26 | 2007-05-01 | Eisai R&D Man Co Ltd | Genetically modified microorganism and process for production of macrolide compound using the microorganism |
| CN101282967B (zh) * | 2005-10-13 | 2011-01-26 | 卫材R&D管理有限公司 | 普拉二烯内酯b和普拉二烯内酯d的全合成 |
| EP2136209A4 (fr) | 2007-03-05 | 2010-10-27 | Eisai R&D Man Co Ltd | Procédé pour l'examen d'une action d'un agent anti-cancéreux utilisant un défaut d'épissage en tant que mesure |
| US20080312317A1 (en) | 2007-04-12 | 2008-12-18 | Eisai R&D Management Co., Ltd. | 12 membered-ring macrolactam derivatives |
| MY195081A (en) | 2014-05-15 | 2023-01-09 | Eisai R&D Man Co Ltd | Pladienolide Pyridine Compounds and Methods of use |
-
2016
- 2016-11-17 IL IL259198A patent/IL259198B2/en unknown
- 2016-11-17 MD MDE20180923T patent/MD3377485T2/ro unknown
- 2016-11-17 US US15/529,798 patent/US10745387B2/en active Active
- 2016-11-17 MX MX2021001441A patent/MX392475B/es unknown
- 2016-11-17 JP JP2017528992A patent/JP6312282B2/ja active Active
- 2016-11-17 CA CA3004623A patent/CA3004623C/fr active Active
- 2016-11-17 RU RU2018121610A patent/RU2743349C2/ru active
- 2016-11-17 AU AU2016357433A patent/AU2016357433B2/en active Active
- 2016-11-17 WO PCT/US2016/062525 patent/WO2017087667A1/fr not_active Ceased
- 2016-11-17 MX MX2018006155A patent/MX379655B/es unknown
- 2016-11-17 BR BR112018009995-3A patent/BR112018009995B1/pt active IP Right Grant
- 2016-11-17 SG SG10201913045PA patent/SG10201913045PA/en unknown
- 2016-11-17 CN CN201680067749.5A patent/CN108473479B/zh active Active
- 2016-11-17 ES ES16805664T patent/ES2757174T3/es active Active
- 2016-11-17 SG SG11201803519YA patent/SG11201803519YA/en unknown
- 2016-11-17 KR KR1020187016598A patent/KR20180083376A/ko active Pending
- 2016-11-17 RU RU2021102393A patent/RU2021102393A/ru unknown
- 2016-11-17 EP EP16805664.6A patent/EP3377485B1/fr active Active
-
2018
- 2018-03-16 JP JP2018049098A patent/JP6353620B1/ja active Active
-
2020
- 2020-07-17 US US16/932,627 patent/US20200361915A1/en not_active Abandoned
-
2021
- 2021-02-15 AU AU2021200974A patent/AU2021200974B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201803519YA (en) | A solid state form of pladienolide pyridine compounds and methods of use | |
| SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
| SG11201907870VA (en) | Compositions and methods for inhibition of lineage specific proteins | |
| SG11201811290VA (en) | Compositions and methods for the depletion of cd117+cells | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201811148SA (en) | Cell penetrating peptide (cpp)-mediated ev loading | |
| SG11201808682XA (en) | Silicone atoms containing ivacaftor analogues | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201805451TA (en) | Immune effector cell therapies with enhanced efficacy | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201811152YA (en) | Uses of extracellular vesicle comprising a fusion protein having fc binding capacity | |
| SG11201805872SA (en) | Chimeric antigen receptors targeting epidermal growth factor receptor variant iii | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201908624SA (en) | Aryl hydrocarbon receptor antagonists and uses thereof | |
| SG11201808762XA (en) | Diagnostic methods for patient specific therapeutic decision making in cancer care | |
| SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201808920RA (en) | Genome editing of human neural stem cells using nucleases | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201808710UA (en) | Novel immunogenic cd1d binding peptides | |
| SG11201807965YA (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| SG11201805680SA (en) | Methods and compositions for the treatment of neurologic disease | |
| SG11201809252YA (en) | Methods for determining dpp3 and therapeutic methods | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression |